These cancers often have loss-of-function mutations in the NF2 gene, which encodes for Merlin, a protein that activates the Hippo pathway and inhibits YAP/TAZ-TEAD-mediated gene transcription. By blocking TEAD, inhibitors aim to restore the balance of the Hippo pathway and prevent the proliferation and survival of tumor cells. These cancers can benefit from Pan-TEAD inhibitors.